Peer-influenced content. Sources you trust. No registration required. This is HCN.
Oncology Learning Network
Osimertinib plus datopotamab deruxtecan produced 20.5-month median duration of response at the 6 mg/kg dose in EGFR-mutated NSCLC after first-line osimertinib progression in the ORCHARD platform substudy.
Hematology/Oncology April 28th 2026
Medical News Today (MNT)
Higher Healthy Eating Index scores and elevated oral contraceptive use co-occurred with young-onset lung cancer in a 187-patient nonsmoker cohort presented at AACR.
Cancer Therapy Advisor
The current real-world cohort study examines long-term survival outcomes in the 5 years after a COVID-19 hospitalization for adults with a solid malignancy. The study assessed the impact of vaccination status, vaccine platform, primary tumor site, and cancer treatment.
Medical Oncology April 14th 2026
MDLinx
“Second-line therapy should not be dismissed outright in platinum-refractory or early-relapsing disease. It remains a relevant part of comprehensive care.” — Tingting Tan, MD, PhD, City of Hope
Internal Medicine March 17th 2026
“Patients with stage IB-IIIA or IIB disease should be considered for neoadjuvant and/or adjuvant systemic therapy based on biomarker testing for PD-L1 status, EGFR mutations, and ALK gene fusions.” — NCCN NSCLC Guidelines, Version 3, 2026
Medical Oncology February 17th 2026
Oncology News Central (ONC)
“Progress is sort of stepwise. How do we make things better? And what we see with FLAURA2 is that we do see an improvement in survival – a meaningful improvement in survival.” – Dr. Stephen Liu
Medical Oncology September 15th 2025